Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025
Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotech company focused on adaptive immune system applications, has scheduled its Q2 2025 financial results announcement for August 5, 2025 after market close.
The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can access the live webcast through the company's website investor section, with a replay available within 24 hours after the event.
Adaptive Biotechnologies (Nasdaq: ADPT), un'azienda biotecnologica in fase commerciale specializzata nelle applicazioni del sistema immunitario adattativo, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 5 agosto 2025 dopo la chiusura del mercato.
L'azienda terrà una conference call e una webcast alle 13:30 PT / 16:30 ET per discutere i risultati. Gli investitori potranno accedere alla diretta streaming attraverso la sezione investitori del sito web aziendale, con una replica disponibile entro 24 ore dall'evento.
Adaptive Biotechnologies (Nasdaq: ADPT), una empresa biotecnológica en etapa comercial centrada en aplicaciones del sistema inmunológico adaptativo, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 5 de agosto de 2025 después del cierre del mercado.
La compañía realizará una llamada de conferencia y una transmisión en vivo a las 1:30 PM PT / 4:30 PM ET para discutir los resultados. Los inversores pueden acceder a la transmisión en vivo a través de la sección de inversores en el sitio web de la empresa, con una repetición disponible dentro de las 24 horas posteriores al evento.
Adaptive Biotechnologies (나스닥: ADPT)는 적응 면역 시스템 응용 분야에 중점을 둔 상업 단계의 바이오테크 기업으로, 2025년 2분기 재무 결과 발표를 2025년 8월 5일 시장 마감 후에 예정하고 있습니다.
회사는 결과를 논의하기 위해 오후 1:30 PT / 오후 4:30 ET에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 투자자들은 회사 웹사이트의 투자자 섹션을 통해 생중계에 접속할 수 있으며, 이벤트 종료 후 24시간 이내에 다시보기 서비스를 이용할 수 있습니다.
Adaptive Biotechnologies (Nasdaq : ADPT), une société biotechnologique en phase commerciale axée sur les applications du système immunitaire adaptatif, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 5 août 2025 après la clôture du marché.
La société organisera une conférence téléphonique et une diffusion en direct à 13h30 PT / 16h30 ET pour discuter des résultats. Les investisseurs peuvent accéder à la diffusion en direct via la section investisseurs du site web de la société, avec une rediffusion disponible dans les 24 heures suivant l'événement.
Adaptive Biotechnologies (Nasdaq: ADPT), ein Biotechnologieunternehmen in der kommerziellen Phase mit Schwerpunkt auf Anwendungen des adaptiven Immunsystems, hat die Bekanntgabe der Finanzergebnisse für das 2. Quartal 2025 für den 5. August 2025 nach Börsenschluss geplant.
Das Unternehmen wird um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen. Investoren können den Live-Webcast über den Investor-Bereich der Unternehmenswebsite verfolgen; eine Aufzeichnung wird innerhalb von 24 Stunden nach der Veranstaltung verfügbar sein.
- None.
- None.
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2025 after market close on Tuesday, August 5, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
When will Adaptive Biotechnologies (ADPT) report Q2 2025 earnings?
What time is the Adaptive Biotechnologies Q2 2025 earnings call?
How can I access Adaptive Biotechnologies' Q2 2025 earnings webcast?
Will Adaptive Biotechnologies' Q2 2025 earnings call be available for replay?
